检索结果 - Enke, Aaron

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours

    Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours 由 Moore, Kathleen N, Bauer, Todd M, Falchook, Gerald S, Chowdhury, Swapan, Patel, Chirag, Neuwirth, Rachel, Enke, Aaron, Zohren, Fabian, Patel, Manish R

    出版 2018
    获取全文 获取全文 获取全文
    Text
    加到收藏夹
    Saved in:
  2. 2
    Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes

    Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes 由 Yap, Timothy A., Hamilton, Erika, Bauer, Todd, Dumbrava, Ecaterina E., Jeselsohn, Rinath, Enke, Aaron, Hurley, Sabrina, Lin, Kevin K., Habeck, Jenn, Giordano, Heidi, Shapiro, Geoffrey I.

    出版 2022
    获取全文 获取全文 获取全文
    Text
    加到收藏夹
    Saved in:
  3. 3
    Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

    Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer 由 Voss, Martin H., Gordon, Michael S., Mita, Monica, Rini, Brian, Makker, Vicky, Macarulla, Teresa, Smith, David C., Cervantes, Andrés, Puzanov, Igor, Pili, Roberto, Wang, Ding, Jalal, Shadia, Pant, Shubham, Patel, Manish R., Neuwirth, Rachel l., Enke, Aaron, Shou, Yaping, Sedarati, Farhad, Faller, Douglas V., Burris, Howard A.

    出版 2020
    获取全文 获取全文 获取全文
    Text
    加到收藏夹
    Saved in:

检索工具: